Pfizer -BioNtech seeks USFDA nod for COVID vaccine boosters for adults
New Delhi: Pfizer Inc and BioNTech on Tuesday requested the U.S. Food and Drug Administration (FDA) to authorize booster doses of their COVID-19 vaccine in all adults, presenting recent data showing the shot would help prevent disease across ages.
Over the past several months, the FDA has authorized Pfizer's boosters for people who are immunocompromised, those who are aged 65 and above, all people at high risk of severe disease, and people who are regularly exposed to the virus.
Pfizer previously requested authorization for all people aged 16 or over, but the FDA held back on extending boosters to everyone, partly because there was not enough evidence of waning immunity or of the benefit of boosters in younger people.
Pfizer said it would present data from a large clinical study which last month showed that a booster dose of its vaccine was 95.6% effective against the coronavirus when compared to a vaccinated group that did not get the third shot.
Read also: USFDA delays nod to Moderna COVID vaccine for teenagers
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.